{"id":"W4379649489","doi":"10.1136/annrheumdis-2023-eular.2513","title":"POS1539 SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGICS: 3-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 2 STUDY","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research","funders":"Leeds Biomedical Research Centre; University of Leeds; Genentech; Griffith University; Janssen Scientific Affairs; McGill University; University of Ottawa; Celgene; Gilead Sciences; University of Washington; Eli Lilly and Company; GlaxoSmithKline; Ottawa Hospital Research Institute; Amgen","keywords":"Medicine; Psoriatic arthritis; Adverse effect; Internal medicine; Psoriasis; Psoriasis Area and Severity Index; Placebo; Rheumatology; Ustekinumab; Clinical endpoint; Tolerability; Randomized controlled trial; Gastroenterology; Adalimumab; Arthritis; Rheumatoid arthritis; Immunology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001541398,0.000836832,0.002158275,0.0002851224,0.0003147721,0.001229037,0.0003939581,0.0009837174,0.002128201],"category_scores_gemma":[0.00115678,0.0003447327,0.002128555,0.0004265053,0.0005493297,0.0009859256,0.0002488574,0.002059242,0.0007141529],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005709401,"about_ca_system_score_gemma":0.0005781386,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005034267,"about_ca_topic_score_gemma":0.001366138,"domain_scores_codex":[0.9995257,0.0001876585,0.00003793467,0.00007542828,0.0000775531,0.00009581682],"domain_scores_gemma":[0.9991549,0.0002423228,0.0002750981,0.00006873459,0.00007217564,0.0001867194],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7425041,0.008060066,0.03787509,0.001504558,0.006210563,0.0004998827,0.000172868,0.003749916,0.01538191,0.0004525409,0.006445643,0.1771429],"study_design_scores_gemma":[0.421492,0.3227436,0.22193,0.0003507566,0.008432696,0.002378016,0.0003544401,0.0052398,0.005481272,0.001128551,0.01025743,0.0002114996],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9897407,0.006130237,0.0002422058,0.0003450392,0.0001031557,0.0001869019,0.001315495,0.00005358665,0.001882766],"genre_scores_gemma":[0.9938561,0.002179667,0.0002233769,0.0006724458,0.000113123,0.0001304932,0.001947644,0.00001582368,0.0008613336],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002158275,"threshold_uncertainty_score":0.00815177,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02439458694575209,"score_gpt":0.2758261132775698,"score_spread":0.2514315263318177,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}